Asperuloside stimulates metabolic function in rats across several organs under high-fat diet conditions, acting like the major ingredient of Eucommia leaves with anti-obesity activity.
Asperuloside stimulates metabolic function in rats across several organs under high-fat diet conditions, acting like the major ingredient of Eucommia leaves with anti-obesity activity.
复制标题
DOI：
10.1017/jns.2012.12
复制
发表时间：
2012
影响因子：
2.5
通讯作者：
Nishibe, Sansei
中科院分区：
文献类型：
--
作者：
Fujikawa, Takahiko;Hirata, Tetsuya;Hosoo, Shingo;Nakajima, Kenji;Wada, Atsunori;Yurugi, Yutaka;Soya, Hideaki;Matsui, Takashi;Yamaguchi, Akihiko;Ogata, Masato;Nishibe, Sansei
杜仲叶（Europeanulmoides奥利弗）含有绿原酸（咖啡酸衍生物）和京尼平苷酸以及用于饮料的环烯醚萜苷（ASP）。我们使用代谢综合征大鼠模型，通过喂养35%的高脂饮食（HFD），以检查潜在的抗肥胖和抗代谢综合征的作用和机制的长期管理ASP。将这些效果与表现出抗肥胖效果的阳性对照品杜仲叶提取物（ELE）进行比较。共6只大鼠分为5组进行了为期3个月的研究。ASP抑制体重，内脏脂肪重量，食物摄入量和循环水平的葡萄糖，胰岛素和脂质，并增加血浆脂联素水平在大鼠的HFD。除了对血糖水平的影响外，这些作用与ELE相似。RT-PCR研究表明，ASP（与已知具有抗肥胖作用的ELE类似）降低异柠檬酸脱氢酶3α、NADH脱氢酶黄素蛋白1（Comp I）mRNA和脂肪酸合成酶水平（白色脂肪组织），肉毒碱棕榈酰转移酶1α和酰基CoA脱氢酶、极长链mRNA水平增加（肝脏），以及Glut 4、柠檬酸合酶、异柠檬酸脱氢酶3α、琥珀酰CoA合酶增加，HFD条件下过氧化物酶体3-酮脂酰-CoA硫解酶、二氢硫辛酰胺琥珀酰转移酶和琥珀酸脱氢酶mRNA水平（骨骼肌）。有趣的是，ASP给药导致HFD喂养大鼠棕色脂肪组织中解偶联蛋白1（UCP 1）的mRNA水平显著增加; ELE不影响UCP 1的表达。ELE中除了ASP之外的许多成分可以抵消UCP 1表达的增加。这些结果表明，长期给予ASP刺激HFD喂养大鼠的抗肥胖和抗代谢综合征活性在几个器官，类似于ELE管理，因此，ASP可能是ELE的重要成分。
Eucommia leaves (Eucommia ulmoides Oliver) contain chlorogenic acid (a caffeic acid derivative) and geniposidic acid and asperuloside (ASP), iridoid glucosides used in beverages. We used a metabolic syndrome rat model, produced by feeding a 35 % high-fat diet (HFD), to examine potential anti-obesity and anti-metabolic syndrome effects and mechanisms of chronic administration of ASP. These effects were compared with Eucommia leaf extract (ELE), the positive control, which exhibits anti-obesity effects. A total of six rats were studied for 3 months in five groups. ASP suppressed body weight, visceral fat weight, food intake and circulating levels of glucose, insulin and lipids, and increased the plasma adiponectin level in rats on a HFD. These effects are similar to those of ELE, except for the influence on the plasma glucose level. RT–PCR studies showed that ASP (like ELE with known anti-obesity effects) diminished isocitrate dehydrogenase 3α, NADH dehydrogenase flavoprotein 1 (Comp I) mRNA and fatty acid synthase levels (white adipose tissue), increased carnitine palmitoyltransferase 1α and acyl-CoA dehydrogenase, very-long-chain mRNA levels (liver), and increased Glut4, citrate synthase, isocitrate dehydrogenase 3α, succinyl CoA synthase, peroxisomal 3-ketoacyl-CoA thiolase, dihydrolipoamide succinyl transferase and succinate dehydrogenase mRNA levels (skeletal muscle) under HFD conditions. Interestingly, ASP administration resulted in significantly increased mRNA levels of uncoupling protein 1 (UCP1) in the brown adipose tissue of HFD-fed rats; ELE did not affect the expression of UCP1. The increased expression of UCP1 may be negated by many ingredients other than ASP in the ELE. These findings suggest that chronic administration of ASP stimulates anti-obesity and anti-metabolic syndrome activity in HFD-fed rats across several organs, similar to ELE administration; thus, ASP may be an important ingredient of ELE.